MX384261B - Metodos de tratamiento para enfermedades colestasicas y fibroticas. - Google Patents

Metodos de tratamiento para enfermedades colestasicas y fibroticas.

Info

Publication number
MX384261B
MX384261B MX2018012287A MX2018012287A MX384261B MX 384261 B MX384261 B MX 384261B MX 2018012287 A MX2018012287 A MX 2018012287A MX 2018012287 A MX2018012287 A MX 2018012287A MX 384261 B MX384261 B MX 384261B
Authority
MX
Mexico
Prior art keywords
cholestatic
fibrotic diseases
treatment methods
nitro
tizoxanide
Prior art date
Application number
MX2018012287A
Other languages
English (en)
Other versions
MX2018012287A (es
Inventor
Carole Belanger
Emilie Negro
Philippe Delataille
Pierre Daubersies
Raphaël Darteil
Robert Walczak
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2018012287A publication Critical patent/MX2018012287A/es
Publication of MX384261B publication Critical patent/MX384261B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere al compuesto [2-[(5-nitro-1,3-tiazol-2-il)carbamoil]fenil]etanoato (Nitazoxanida) o 2-hidroxi-N-(5-nitro-2-tiazolil)benzamida (Tizoxanida) para tratar enfermedades colestásicas y fibróticas.
MX2018012287A 2016-04-11 2017-03-13 Metodos de tratamiento para enfermedades colestasicas y fibroticas. MX384261B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305425 2016-04-11
PCT/EP2017/055878 WO2017178172A1 (en) 2016-04-11 2017-03-13 Methods of treatment for cholestatic and fibrotic diseases

Publications (2)

Publication Number Publication Date
MX2018012287A MX2018012287A (es) 2019-02-07
MX384261B true MX384261B (es) 2025-03-14

Family

ID=55755536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012287A MX384261B (es) 2016-04-11 2017-03-13 Metodos de tratamiento para enfermedades colestasicas y fibroticas.

Country Status (24)

Country Link
US (7) US20170290812A1 (es)
EP (3) EP3777855B1 (es)
JP (1) JP6894923B2 (es)
KR (1) KR102431257B1 (es)
CN (1) CN109069648B (es)
AU (1) AU2017249602B2 (es)
CA (1) CA3019399A1 (es)
DK (2) DK3442580T3 (es)
EA (2) EA202191466A1 (es)
ES (3) ES2935185T3 (es)
HR (1) HRP20201954T1 (es)
HU (2) HUE060671T2 (es)
IL (1) IL262052B (es)
LT (1) LT3442580T (es)
MD (1) MD3442580T2 (es)
MX (1) MX384261B (es)
MY (1) MY195437A (es)
PH (1) PH12018502142B1 (es)
PL (1) PL3442580T3 (es)
PT (2) PT3777855T (es)
SG (2) SG11201808402RA (es)
SI (1) SI3442580T1 (es)
WO (1) WO2017178172A1 (es)
ZA (1) ZA201807389B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017178174A1 (en) * 2016-04-11 2017-10-19 Genfit Methods of treatment of cholestasis and fibrosis
MX384261B (es) 2016-04-11 2025-03-14 Genfit Metodos de tratamiento para enfermedades colestasicas y fibroticas.
EP3595656A1 (en) * 2017-03-13 2020-01-22 Genfit Pharmaceutical compositions for combination therapy
AU2018238577B2 (en) * 2017-03-21 2023-02-02 Novalead Pharma Inc. Therapeutic agent for phosphodiesterase inhibition and its related disorders
JP7365054B2 (ja) * 2017-11-17 2023-10-19 ケスター，ヒューバート リンパ管平滑筋腫症及びその他の疾患に使用するための［２－［（５－ニトロ－１，３－チアゾール－２－イル）カルバモイル］フェニル］エタノエート
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
CN113677336B (zh) 2019-04-10 2024-04-30 基恩菲特公司 包含式(i)化合物和glp-1受体激动剂的组合疗法
KR20210151854A (ko) * 2019-04-12 2021-12-14 장피트 산화 스트레스와 관련된 질환의 치료에 사용하기 위한 니타족사니드 및 티아졸리드
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
CN110478357A (zh) * 2019-07-23 2019-11-22 哈尔滨医科大学 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
AU2020376223A1 (en) 2019-10-28 2022-06-02 Genfit Combination therapy having antioxydant properties
CN113398125B (zh) * 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
US20240000754A1 (en) * 2020-11-17 2024-01-04 Genfit Methods of treatment of liver failure
CN116507343A (zh) * 2020-11-17 2023-07-28 基恩菲特公司 治疗肝衰竭的方法
CN115197164B (zh) * 2021-04-12 2025-04-01 杜心赟 新型噻唑类化合物及其制备方法和用途
CN116077502B (zh) * 2021-11-05 2025-12-23 广州医科大学附属妇女儿童医疗中心 叶酸在预防、诊断和治疗胆道闭锁中的应用
CA3267824A1 (en) * 2022-10-04 2024-04-11 Genfit NITAZOXANIDE FOR THE TREATMENT OF LIVER FAILURE
CN116911513B (zh) * 2023-02-07 2024-07-26 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用
WO2025063816A1 (ko) * 2023-09-21 2025-03-27 오토텔릭바이오 주식회사 티아졸 유도체 화합물을 포함하는 자궁 섬유화증 치료용 조성물
CN117838690B (zh) * 2023-10-09 2024-09-13 中国药科大学 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
KR20060088537A (ko) 2003-09-06 2006-08-04 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ-결합 카세트 수송체의 조절자
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US20100056505A1 (en) 2005-11-21 2010-03-04 Biogen Idec Ma Inc. Substituted Pyrazalones
UA100840C2 (ru) 2006-01-09 2013-02-11 РОМАРК ЛЕБОРЕТЕРИЗ, Эл.Си. Композиция для лечения вирусного гепатита
EP1983980A4 (en) 2006-01-25 2010-05-05 Synta Pharmaceuticals Corp THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY
GB0619500D0 (en) 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
ES2550755T3 (es) 2007-08-03 2015-11-12 Romark Laboratories, L.C. Compuestos de tiazolida sustituidos con alquilsulfonilo
WO2009023509A2 (en) * 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
KR101045572B1 (ko) 2007-08-14 2011-07-01 주식회사 엘지화학 Ｃｌｏｓｔｒｉｄｉｕｍ ｐｒｏｐｉｏｎｉｃｕｍ 유래의프로피오닐―ＣｏＡ 트랜스퍼라아제 변이체 및 상기변이체를 이용한 락테이트 중합체 또는 락테이트공중합체의 제조방법
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
WO2009039248A2 (en) 2007-09-18 2009-03-26 Stanford University Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
US20100016262A1 (en) 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
WO2010107739A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
EP3078377A3 (en) 2009-05-12 2017-04-05 Romark Laboratories, L.C. Nitazoxanide and tizoxanide as anti-viral agents
AU2010264479B2 (en) 2009-06-26 2017-06-01 Romark Laboratories L.C. Compounds and methods for treating influenza
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CA2781054A1 (en) 2009-11-16 2011-05-19 Chung K. Chu 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
MX337711B (es) 2010-08-27 2016-03-15 Calcimedica Inc Compuestos que modulan el calcio intracelular.
NZ611410A (en) 2010-11-01 2016-02-26 Romark Lab Lc Alkylsulfinyl-substituted thiazolide compounds
AU2012223528A1 (en) 2011-03-02 2013-10-24 Joseph M. Fayad Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection
BR112013029505A2 (pt) 2011-05-16 2020-01-07 Romark Laboratories L.C. Composição farmacêutica, e, uso de um composto
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
WO2013082469A2 (en) 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
KR20170081228A (ko) 2014-11-11 2017-07-11 로마크 레버러토리즈, 엘.씨. 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법
US20190070154A1 (en) 2015-06-24 2019-03-07 Duke University New methods of use for an anti-diarrhea agent
MX384261B (es) 2016-04-11 2025-03-14 Genfit Metodos de tratamiento para enfermedades colestasicas y fibroticas.
WO2017178174A1 (en) 2016-04-11 2017-10-19 Genfit Methods of treatment of cholestasis and fibrosis
KR102410951B1 (ko) 2016-04-11 2022-06-20 장피트 담즙정체성 및 섬유증 질환의 치료 방법

Also Published As

Publication number Publication date
EA202191466A1 (ru) 2021-12-31
US10117856B2 (en) 2018-11-06
MD3442580T2 (ro) 2021-04-30
PT3442580T (pt) 2020-12-23
EP3442580A1 (en) 2019-02-20
NZ746668A (en) 2024-12-20
DK3442580T3 (da) 2020-12-21
MX2018012287A (es) 2019-02-07
KR102431257B1 (ko) 2022-08-10
CN109069648A (zh) 2018-12-21
US20170290812A1 (en) 2017-10-12
EP3777855A1 (en) 2021-02-17
US20180092886A1 (en) 2018-04-05
PH12018502142A1 (en) 2019-07-29
PT3777855T (pt) 2023-01-10
HUE060671T2 (hu) 2023-04-28
LT3442580T (lt) 2020-12-28
PL3442580T3 (pl) 2021-04-06
JP2019513761A (ja) 2019-05-30
WO2017178172A1 (en) 2017-10-19
US11103484B2 (en) 2021-08-31
US20200316031A1 (en) 2020-10-08
HRP20201954T1 (hr) 2021-02-05
EP3442580B1 (en) 2020-09-23
HUE052886T2 (hu) 2021-05-28
US10130613B2 (en) 2018-11-20
SG11201808402RA (en) 2018-10-30
CN109069648B (zh) 2022-01-14
US20180085354A1 (en) 2018-03-29
US10117855B2 (en) 2018-11-06
KR20180129934A (ko) 2018-12-05
ZA201807389B (en) 2020-01-29
AU2017249602B2 (en) 2022-06-16
ES2935185T3 (es) 2023-03-02
ES2928408T3 (es) 2022-11-17
IL262052A (en) 2018-11-29
AU2017249602A1 (en) 2018-10-18
EA201892298A1 (ru) 2019-04-30
DK3777855T3 (da) 2023-01-09
SG10202004425XA (en) 2020-06-29
EP3777854B1 (en) 2022-07-20
US20180092885A1 (en) 2018-04-05
SI3442580T1 (sl) 2021-01-29
EP3777854A1 (en) 2021-02-17
US20190000813A1 (en) 2019-01-03
ES2839453T3 (es) 2021-07-05
IL262052B (en) 2021-12-01
CA3019399A1 (en) 2017-10-19
MY195437A (en) 2023-01-20
BR112018069684A2 (pt) 2019-01-29
US20180092884A1 (en) 2018-04-05
JP6894923B2 (ja) 2021-06-30
PH12018502142B1 (en) 2023-08-11
US10130612B2 (en) 2018-11-20
EP3777855B1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
MX2018012287A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
HUE059624T2 (hu) N-(fenil)-2-(fenil)pirimidin-4-karboxamid származékok és rokon vegyületek HPK1-inhibitorokként rák kezelésére
DK3887360T3 (da) Mikrobiocide thiazolderivater
PL3761980T3 (pl) Związki aminokwasowe i sposoby zastosowania
IL273705B (en) Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
IL256056A (en) Ezh2 inhibitors for treating lymphoma
PT4122464T (pt) Combinações terapêuticas para o tratamento de doenças do fígado
PT3220916T (pt) Método para tratamento de cancro com n-((4,6-dimetil-2-oxo-1,2-di-hidropiridina-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenilo]-3-carboxamida
IL275496A (en) Glycolate oxidase inhibitors to treat the disease
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
PL3805233T3 (pl) ENANCJOMERY (R) I (S) (S)-N-(5-(3-hydroksypirolidyn-1-ylo)-2-morfolinooksazolo[4,5-b]pirydyn-6-ylo)-2-(2-metylopirydyn-4-ylo)oksazolo-4-karboksyamidu jako inhibitory IRAK4 do leczenia nowotworu złośliwego
PT3562486T (pt) Uso de dexmedetomidina sublingual para o tratamento da agitação
IL279260A (en) KDM1A inhibitors for the treatment of diseases
PL3157534T3 (pl) Inhibitory acetylocholinesteraz w leczeniu stanów dermatologicznych
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
DK3240538T3 (da) Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
IL280348A (en) Surface treatment compositions and methods
PL3573620T3 (pl) Kompozycje do leczenia nadciśnienia
HUE064253T2 (hu) Emulziók hüvelyi fertõzések kezelésére
IL289592A (en) Methods for diagnosing the effectiveness of anti-tumor treatment
EP3768229C0 (en) SKIN CONDITION IMPROVING AGENTS
ES2514140A1 (es) Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento
IL290181A (en) Process for the preparation of fluensulfone